Key points
- A single dose of CJC-1295 was associated with IGF-1 levels 1.5 to 3 times higher for 9 to 11 days in healthy adults [1].
- The only randomized clinical-efficacy trial of ipamorelin indexed in PubMed (postoperative ileus, 114 patients analyzed) showed no significant difference vs placebo [2].
- One year of MK-677 in older adults was associated with more fat-free mass, without changes in strength or function, and also with higher fasting glucose and lower insulin sensitivity [3].
- The link between high IGF-1 and cancer comes from population and genetic studies, not from trials of these compounds [4][5].
US status (October 2026): Neither CJC-1295 nor ipamorelin is FDA-approved, and neither has a compounding pathway. MDside providers do not prescribe them.
These compounds raise growth hormone and IGF-1 in humans. What the evidence does not show is a long-term benefit that outweighs the metabolic cost and the open cancer question.
The case for secretagogues starts with GH decline
Growth hormone (GH) secretion declines from mid-puberty throughout life [3]. Hence the idea of secretagogues, compounds that stimulate the pituitary to release more GH. The most searched are CJC-1295 (a GHRH analog), ipamorelin (a ghrelin-receptor agonist) and MK-677 or ibutamoren, which is taken by mouth and is not a peptide, though it is often sold in the same bundles [1][2][3].
CJC-1295 does raise GH and IGF-1
In healthy adults aged 21 to 61, a single dose of CJC-1295 was associated with dose-dependent 2- to 10-fold GH increases for 6 days or more and 1.5- to 3-fold IGF-1 increases for 9 to 11 days, with a half-life of 5.8 to 8.1 days and a cumulative effect with repeat doses. No serious adverse reactions were reported in those trials [1].
- 9 to 11 days: of raised IGF-1 after one CJC-1295 dose [1]
- 114: patients in the only randomized ipamorelin efficacy trial [2]
- About 5 mg/dL: rise in fasting glucose on MK-677 at one year [3]
Ipamorelin has one trial, and it was negative
Ipamorelin has a single randomized clinical-efficacy trial indexed in PubMed: a phase 2 study with 114 patients analyzed after bowel resection, aimed at speeding recovery from postoperative ileus. Median time to a tolerated solid meal was 25.3 vs 32.6 hours (p = 0.15). There was no significant difference vs placebo in the efficacy analyses, although it was well tolerated [2]. We found no human trials on body composition or aging.
MK-677 carries a metabolic cost
The longest study is of MK-677: a 2-year randomized trial (primary endpoints at one year) in 65 healthy adults aged 60 to 81. It brought GH and IGF-1 to young-adult levels. It was associated with a 1.1 kg gain in fat-free mass (vs a 0.5 kg loss on placebo) and a 2.7 kg gain in body weight (vs 0.8 kg), with no change in strength or function. Fasting glucose rose about 5 mg/dL and insulin sensitivity fell. Cortisol rose. The most frequent side effects were increased appetite (which subsided within a few months), transient mild edema and muscle pain [3].
The cancer risk is an inference, neither confirmed nor ruled out
IGF-1 stimulates cell growth, and that is the concern. A 2004 meta-analysis associated higher blood IGF-1 with more prostate cancer (OR 1.49 comparing the 75th with the 25th percentile) and premenopausal breast cancer (OR 1.65), with modest associations that varied by cancer type [4]. An analysis of up to 20 prospective studies plus Mendelian randomization found, per standard deviation of IGF-1, an OR of 1.09 for prostate cancer (1.07 with the genetic method) [5].
Two caveats matter. First, these are associations with the body’s own IGF-1, not trials of secretagogues. Second, we found no study that has measured long-term cancer risk with these compounds.
Sport. The World Anti-Doping Agency’s 2026 Prohibited List explicitly names CJC-1295, ipamorelin, ibutamoren (MK-677) and the GHRPs under S2.2.4, prohibited at all times [6]. If you treat competitive athletes, that alone ends the conversation.
The supporters’ case is real, within approved indications
Secretagogues work on their target: they raise GH and IGF-1 in humans [1][3]. Tesamorelin, a GHRH analog, is approved for excess abdominal fat in HIV. In a pooled analysis of two phase 3 trials with 806 patients, it reduced visceral fat with a treatment effect of 15.4% vs placebo at 26 weeks [7]. MK-677 increased fat-free mass in older adults [3]. Whether they act is settled. The open question is their long-term benefit-risk balance outside those indications.
What this means for your clinic
When a patient asks for a CJC-1295 and ipamorelin stack, the honest answer is that the hormones move and the outcomes are unproven. Products sold under these names come through channels labeled “research use only”, outside any compounding pathway. If you want a peptide line that stays inside the rules, start from the status tracker and the peptide program structure we use.
References
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. Link
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. PMID 25331030. Link
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11. PMID 18981485. Link
- Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-53. PMID 15110491. Link
- Watts EL, et al. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int J Epidemiol. 2023;52(1):71-86. PMID 35726641. Link
- World Anti-Doping Agency. The 2026 Prohibited List (S2.2.4 Growth hormone releasing factors). Link
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PMID 20554713. Link
This is general information, not medical or legal advice. Rules vary by state and change. Confirm your own facts with counsel.